Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Guggenheim reduced Axsome Therapeutics' (AXSM) price target to $250 from $275, maintaining a Buy rating. AXSM's Q3 sales reached $207.6M, up 53% YoY, with strong gross margins. The company reported $259.7M in total revenue, beating estimates, but posted an adjusted loss of $0.25 per share. Analysts remain bullish, with price targets ranging from $238 to $380.

Baird reaffirmed its Outperform rating for Axsome Therapeutics but reduced its price target from $246 to $220, a 10.6% decrease. The new target suggests a 61.8% upside from the Nov 2 closing price of $136.01.

B.Riley reiterated a Buy rating and $300 target on Axsome Therapeutics (AXSM) after its Q3 2026 results. Revenue was $259.7M, up 52% YoY, beating estimates. AUVELITY revenue reached $207.6M, up 53% YoY. B.Riley expects cash flow breakeven in Q4 2026. AXSM stock fell premarket despite strong results.

Axsome Therapeutics reported Q3 2026 revenue of $259.7M, up 52% YoY, with AUVELITY sales at $207.6M. Net loss narrowed to $12.9M. Growth driven by demand in MDD and Alzheimer's disease agitation. Pipeline includes 10 programs with near-term catalysts. Expenses rose due to commercialization efforts, and stock is down 40-45% since launch.

Axsome Therapeutics (AXSM) reported Q3 revenue of $260M, up 52% YoY. AUVELITY sales rose 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company cited growth in prescriptions and prescribers, but noted concerns like higher expenses and limited SYMBRAVO coverage.

Axsome Therapeutics reported Q3 2026 revenue of $259.7M, up 51.9% YoY, with a net loss of $12.9M, narrower than the prior-year quarter. EPS was $(0.25). Sales of AUVELITY, SUNOSI, and SYMBRAVO increased, and the FDA accepted the AXS-12 NDA with a 2027 target date.